Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
AGIOS PHARMACEUTICALS, INC. director Jay T. Backstrom reported equity compensation activity. On July 8, 2026, he acquired 1,447 shares of common stock at no cost, in connection with the exercise/vesting of 1,447 restricted stock units (RSUs). Following these transactions, he directly holds 1,447 common shares and 2,894 RSUs. The RSUs were originally granted on July 8, 2025 and are scheduled to vest in three equal annual installments beginning July 8, 2026.
Agios Pharmaceuticals reports a Schedule 13G showing D. E. Shaw & Co., L.P. and David E. Shaw hold 3,034,031 shares (5.1%) of Common Stock. The filing states shared voting power of 2,863,931 shares and shared dispositive power over 3,034,031 shares. The filing is signed July 2, 2026.
Agios Pharmaceuticals Chief Medical Officer Sarah Gheuens reported routine equity compensation activity and related tax sales. On July 1, 2026, 8,375 restricted stock units converted into an equal number of common shares as part of a scheduled vesting from a July 1, 2023 grant.
To cover tax withholding from this vesting, 4,007 common shares were sold at $37.56 per share under durable automatic sale instructions designed to qualify for the Rule 10b5-1(c) affirmative defense. After these transactions, Gheuens directly holds 84,645 shares of Agios common stock.
AGIO submitted a Form 144 notice listing 4,007 shares of Common Stock associated with the vesting of restricted stock units on 07/01/2026. The filing notes the securities are to be sold through Morgan Stanley Smith Barney LLC. It also records a prior sale of 2,940 shares on 04/02/2026 for $102,047.40 by Sarah Gheuens.
AGIOS PHARMACEUTICALS director Rahul D. Ballal reported equity compensation transactions. He exercised 2,816 restricted stock units into common stock and, after these transactions, directly holds 15,230 common shares.
On the same date, he received 14,950 stock options at an exercise price of $34.16 per share, expiring on June 18, 2036, and 2,927 new restricted stock units. Footnotes state the exercised RSUs were granted on June 18, 2025 and vested on June 18, 2026, while the new RSUs and options were granted on June 18, 2026 and will vest in full on June 18, 2027.
AGIOS PHARMACEUTICALS director Jeffrey D. Capello reported equity awards and vesting activity. On June 18, 2026, 2,816 restricted stock units converted into the same number of common shares, increasing his direct holdings to 10,865 shares.
He also received new grants of 14,950 stock options with an exercise price of $34.16 per share, expiring on June 18, 2036, and 2,927 restricted stock units. According to the footnotes, options and RSUs granted on June 18, 2026 vest in full on June 18, 2027, with vested shares delivered within three business days. Earlier RSUs granted June 18, 2025 vest in full on June 18, 2026. These are compensation-related grants and exercises, not open-market purchases or sales.
AGIOS PHARMACEUTICALS, INC. director Kaye I. Foster-Cheek reported routine equity compensation and an option-related share delivery. On June 18, 2026, she exercised restricted stock units covering 2,816 shares of common stock, increasing her direct holdings to 10,284 shares. She also received a grant of 14,950 stock options with a $34.16 exercise price, expiring on June 18, 2036, and a separate award of 2,927 restricted stock units that will vest in full on June 18, 2027. In addition, 2,200 shares are held indirectly through the Foster Family Revocable Trust. These movements reflect compensation and conversions rather than open-market buying or selling.
AGIOS PHARMACEUTICALS director Jacqualyn A. Fouse reported equity compensation and a routine vesting event. On June 18, 2026, 2,816 restricted stock units vested and were converted into 2,816 shares of common stock, bringing her direct common stock holdings to 154,156 shares.
On the same date, she received new awards of 14,950 stock options with a strike price of $34.16 per share, expiring on June 18, 2036, and 2,927 new restricted stock units. These 2026 option and RSU grants are scheduled to vest in full on June 18, 2027. The filing shows only acquisitions, with no reported share sales.
AGIOS PHARMACEUTICALS director Maykin Ho reported compensation-related equity transactions. She exercised restricted stock units into 2,816 shares of common stock, bringing her direct holdings to 19,848 shares. She also received 14,950 stock options and 2,927 new restricted stock units, which vest in future years.
AGIOS PHARMACEUTICALS, INC. director Catherine Owen Adams reported equity compensation activity involving stock options, restricted stock units (RSUs), and common shares. She exercised RSUs to receive 2,816 shares of common stock, bringing her direct common stock holdings to 10,865 shares.
On the same date she was granted 14,950 stock options with a $34.16 exercise price, vesting fully on June 18, 2027, and 2,927 RSUs that also vest in full on June 18, 2027. Footnotes state earlier RSUs granted June 18, 2025 vested June 18, 2026, with shares delivered within three business days.